Goldstein JA - Search Results

1

Identification of residues 286 and 289 as critical for conferring substrate specificity of human CYP2C9 for diclofenac and ibuprofen.

Klose TS, Ibeanu GC, Ghanayem BI, Pedersen LG, Li L, Hall SD, Goldstein JA. Klose TS, et al. Among authors: goldstein ja. Arch Biochem Biophys. 1998 Sep 15;357(2):240-8. doi: 10.1006/abbi.1998.0826. Arch Biochem Biophys. 1998. PMID: 9735164

2

Transcriptional regulation of human CYP2C genes: functional comparison of CYP2C9 and CYP2C18 promoter regions.

Ibeanu GC, Goldstein JA. Ibeanu GC, et al. Among authors: goldstein ja. Biochemistry. 1995 Jun 27;34(25):8028-36. doi: 10.1021/bi00025a008. Biochemistry. 1995. PMID: 7794915

3

Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in humans.

Goldstein JA, Faletto MB, Romkes-Sparks M, Sullivan T, Kitareewan S, Raucy JL, Lasker JM, Ghanayem BI. Goldstein JA, et al. Biochemistry. 1994 Feb 22;33(7):1743-52. doi: 10.1021/bi00173a017. Biochemistry. 1994. PMID: 8110777

4

Identification of residues 99, 220, and 221 of human cytochrome P450 2C19 as key determinants of omeprazole activity.

Ibeanu GC, Ghanayem BI, Linko P, Li L, Pederson LG, Goldstein JA. Ibeanu GC, et al. Among authors: goldstein ja. J Biol Chem. 1996 May 24;271(21):12496-501. doi: 10.1074/jbc.271.21.12496. J Biol Chem. 1996. PMID: 8647857 Free article.

5

Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin.

Ibeanu GC, Goldstein JA, Meyer U, Benhamou S, Bouchardy C, Dayer P, Ghanayem BI, Blaisdell J. Ibeanu GC, et al. Among authors: goldstein ja. J Pharmacol Exp Ther. 1998 Sep;286(3):1490-5. J Pharmacol Exp Ther. 1998. PMID: 9732415

6

Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs.

Klose TS, Blaisdell JA, Goldstein JA. Klose TS, et al. Among authors: goldstein ja. J Biochem Mol Toxicol. 1999;13(6):289-95. doi: 10.1002/(sici)1099-0461(1999)13:6<289::aid-jbt1>3.0.co;2-n. J Biochem Mol Toxicol. 1999. PMID: 10487415

7

Identification of human CYP2C19 residues that confer S-mephenytoin 4'-hydroxylation activity to CYP2C9.

Tsao CC, Wester MR, Ghanayem B, Coulter SJ, Chanas B, Johnson EF, Goldstein JA. Tsao CC, et al. Among authors: goldstein ja. Biochemistry. 2001 Feb 20;40(7):1937-44. doi: 10.1021/bi001678u. Biochemistry. 2001. PMID: 11329260

8

A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin.

Ibeanu GC, Blaisdell J, Ferguson RJ, Ghanayem BI, Brosen K, Benhamou S, Bouchardy C, Wilkinson GR, Dayer P, Goldstein JA. Ibeanu GC, et al. Among authors: goldstein ja. J Pharmacol Exp Ther. 1999 Aug;290(2):635-40. J Pharmacol Exp Ther. 1999. PMID: 10411572

9

Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes.

Karam WG, Goldstein JA, Lasker JM, Ghanayem BI. Karam WG, et al. Among authors: goldstein ja. Drug Metab Dispos. 1996 Oct;24(10):1081-7. Drug Metab Dispos. 1996. PMID: 8894508

10

Discovery of new potentially defective alleles of human CYP2C9.

Blaisdell J, Jorge-Nebert LF, Coulter S, Ferguson SS, Lee SJ, Chanas B, Xi T, Mohrenweiser H, Ghanayem B, Goldstein JA. Blaisdell J, et al. Among authors: goldstein ja. Pharmacogenetics. 2004 Aug;14(8):527-37. doi: 10.1097/01.fpc.0000114759.08559.51. Pharmacogenetics. 2004. PMID: 15284535

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

641 results

Search Page